CanSino Biologics Yönetim

Yönetim kriter kontrolleri 4/4

CanSino Biologics CEO'su Xuefeng Yu, Jan2009 tarihinde atandı, in görev süresi 15.83 yıldır. in toplam yıllık tazminatı CN¥ 3.97M olup, şirket hissesi ve opsiyonları dahil olmak üzere 64.1% maaş ve 35.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 11.96% ine doğrudan sahiptir ve bu hisseler € 165.30M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 3.1 yıldır.

Anahtar bilgiler

Xuefeng Yu

İcra Kurulu Başkanı

CN¥4.0m

Toplam tazminat

CEO maaş yüzdesi	64.1%
CEO görev süresi	15.8yrs
CEO sahipliği	12.0%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Xuefeng Yu'un ücretlendirmesi CanSino Biologics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-CN¥720m
Jun 30 2024	n/a	n/a	-CN¥867m
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥5m	CN¥2m	-CN¥909m

Tazminat ve Piyasa: Xuefeng 'nin toplam tazminatı ($USD 547.24K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.63M ).

Tazminat ve Kazançlar: Xuefeng 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Xuefeng Yu (59 yo)

15.8yrs

Görev süresi

CN¥3,965,000

Tazminat

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% € 165.3m
Tao Zhu	Co-Founder	15.8yrs	CN¥4.42m	7.27% € 100.5m
Dongxu Qiu	Co-Founder	15.8yrs	CN¥3.74m	11.42% € 157.9m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.5yrs	CN¥3.93m	0.0081% € 112.0k
Jing Wang	Chief Commercial Officer	3.2yrs	CN¥4.57m	0.0072% € 99.7k
Chunlin Xin	Senior Director of New Technology Department	7yrs	Veri yok	Veri yok
Yonghui Wu	Vice President of Marketing	no data	Veri yok	Veri yok
Jin Cui	Board Secretary	5.7yrs	Veri yok	Veri yok
Ming King Chiu	Joint Company Secretary	5.7yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: CJH 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Xuefeng Yu	Co-Founder	15.8yrs	CN¥3.97m	11.96% € 165.3m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.4yrs	CN¥3.93m	0.0081% € 112.0k
Jing Wang	Chief Commercial Officer	3.1yrs	CN¥4.57m	0.0072% € 99.7k
George R. Siber	Co-Chair of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Shan Lu	Member of the Scientific Advisory Board	2.5yrs	Veri yok	Veri yok
Shuifa Gui	Independent Non-Executive Director	5yrs	CN¥300.00k	Veri yok
Luis Barreto	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	Veri yok	Veri yok
Jianzhong Liu	Independent Non-Executive Director	5yrs	CN¥300.00k	0.00040% € 5.5k
Liming Li	Co-Chair of Scientific Advisory Board	1.8yrs	Veri yok	Veri yok
Jingren Zhang	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Leung Cheung Yiu	Independent Non-Executive Director	no data	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CJH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

CanSino Biologics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Less than half of directors are independent

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

Recent updates

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.58 loss in 3Q 2023)

New minor risk - Profitability

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

High number of new directors

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

First quarter 2024 earnings released: CN¥0.69 loss per share (vs CN¥0.57 loss in 1Q 2023)

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

Full year 2023 earnings released: CN¥6.01 loss per share (vs CN¥3.68 loss in FY 2022)

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings released: CN¥5.87 loss per share (vs CN¥3.68 loss in FY 2022)

Less than half of directors are independent

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold €414k worth of stock

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Now 31% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Less than half of directors are independent

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.06 loss in 1Q 2021)

Less than half of directors are independent

CanSino Biologics Inc. to Report Q1, 2022 Results on Apr 28, 2022

Cansino Biologics Inc. Proposes Dividend for the Financial Year Ended 31 December 2021

Less than half of directors are independent

CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CanSino Biologics Inc. announces Convidecia Approve as Heterologous Booster in China

Investor sentiment deteriorated over the past week

CanSino Biologics Inc. (SEHK:6185) announces an Equity Buyback for CNY 300 million worth of its shares.

CanSinoBIO's Shows Encouraging Results for Inhaled COVID-19 Vaccine as Heterologous Booster

CanSino Biologics Inc. Announces Approval for its MCV4 Product Menhycia in China

CanSino Biologics Inc. Announces the National Medical Products Administration of China Grants New Drug Approval to Menhycia

CanSino Biologics Inc. Announces Convidecia™ Phase III Results Published in The Lancet

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week